Ligand Pharmaceuticals Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
Net income: US$53.8m (up from US$5.22m loss in FY 2022). Profit margin: 41% (up from net loss in FY 2022). EPS: US$3.11 (up from US$0.31 loss in FY 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period Ligand Pharmaceuticals Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 54%. Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are up 23% from a week ago. Risk Analysis We should say that we've discovered 3 warning signs for Ligand Pharmaceuticals (1 is significant!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) si
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand and Agenus Enter Into $100 Million Royalty Financing AgreementBusiness Wire
- Don't Overlook These Top Medical Stocks as Q1 Earnings Approach [Yahoo! Finance]Yahoo! Finance
- Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio [Seeking Alpha]Seeking Alpha
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024Business Wire
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $95.00 price target on the stock.MarketBeat
LGND
Earnings
- 2/27/24 - Beat
LGND
Sec Filings
- 5/7/24 - Form 8-K
- 5/2/24 - Form 4
- 4/26/24 - Form 4
- LGND's page on the SEC website